Literature DB >> 15851048

Human cervical lymphadenopathy: evaluation with in vivo 1H-MRS at 1.5 T.

A D King1, D K Yeung, A T Ahuja, E H Y Yuen, S F M Ho, G M K Tse, A C van Hasselt.   

Abstract

AIM: To evaluate the feasibility of performing in vivo proton magnetic resonance spectroscopy ((1)H-MRS) of cervical lymph nodes, and the clinical usefulness of the technique in the characterization of cervical lymphadenopathy.
MATERIALS AND METHODS: Cervical lymphadenopathy was examined in 20 individuals with malignant disease, i.e. 10 with squamous cell carcinoma (SCC), 6 with undifferentiated carcinoma (UDC) and 4 with non-Hodgkin's lymphoma (NHL). Cervical lymphadenopathy was also examined in 4 individuals with benign disease, i.e. 3 with tuberculosis (TB) and 1 with Castleman's disease. A point-resolved spectroscopic sequence with echo times (TE) of 136 and 272 ms and a time-domain spectral fitting procedure were used to estimate peak amplitude of choline (Cho), creatine (Cr) and unsuppressed water. Cho/Cr and Cho/water ratios were measured for each lesion. The mean ratio for each lesion group was obtained and results were compared statistically.
RESULTS: At TE of 136 ms, spectra were interpretable in all 24 cases and a Cr peak was identified with post-processing in 15 cases. The Cho/Cr and Cho/water ratios for NHL were 9.1 +/- 5.2 and 1.7 +/- 0.2 x 10(-3), for UDC were 4.4 +/- 0.9 and 1.2 +/- 0.4 x 10(-3), and for SCC were 2.1 +/- 0.6 and 0.5 +/- 0.3 x 10(-3), respectively. Both Cho/Cr and Cho/water ratios for UDC were significantly higher than SCC (p = 0.002 and 0.026, respectively). At TE of 272 ms, spectra were interpretable in 22 of 24 cases and a Cr peak was identified with post-processing in 11 cases. Cho/Cr and Cho/water ratios for NHL were 5.4 and 4.6 +/- 1.4 x 10(-3), for UDC were 4.2 +/- 1.5 and 2.6 +/- 1.0 x 10(-3) and for SCC were 2.5 +/- 1.1 and 1.3 +/- 0.6 x 10(-3), respectively. The Cho/water ratio for UDC was significantly higher than for SCC (p = 0.04). The Cho/Cr ratio for UDC was also higher than for SCC, but this difference was not statistically significant (p = 0.07). Neither Cho nor Cr was detected in the 3 cases of TB.
CONCLUSION: In vivo (1)H-MRS is a feasible technique for the evaluation of cervical lymph nodes and it offers potential as a clinical tool in the investigation of cervical lymphadenopathy. However, further studies with larger patient cohorts are needed to validate the findings of this initial report.

Entities:  

Mesh:

Year:  2005        PMID: 15851048     DOI: 10.1016/j.crad.2004.11.012

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

1.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  Monitoring of treatment response after chemoradiotherapy for head and neck cancer using in vivo 1H MR spectroscopy.

Authors:  Ann D King; David K W Yeung; Kwok-Hung Yu; Frankie K F Mo; Chen-Wen Hu; Kunwar S Bhatia; Gary M K Tse; Alexander C Vlantis; Jeffrey K T Wong; Anil T Ahuja
Journal:  Eur Radiol       Date:  2009-08-05       Impact factor: 5.315

3.  Malignant tumors and chronic infections in the masticator space: preliminary assessment with in vivo single-voxel 1H-MR spectroscopy.

Authors:  Q Yu; J Yang; P Wang
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-09       Impact factor: 3.825

4.  Can magnetic resonance spectroscopy differentiate malignant and benign causes of lymphadenopathy? An in-vitro approach.

Authors:  Lionel Buré; Louis-Martin Boucher; Miriam Blumenkrantz; Stefan Schob; Pierre Lafaye de Micheaux; Caroline Reinhold; Benoit Gallix
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

Review 5.  Multimodality imaging of head and neck cancer.

Authors:  A D King
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

Review 6.  ChoK-Full of Potential: Choline Kinase in B Cell and T Cell Malignancies.

Authors:  Samantha Gokhale; Ping Xie
Journal:  Pharmaceutics       Date:  2021-06-20       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.